Centogene_Logo.png
CENTOGENE Reports Third Quarter 2021 Financial Results
November 24, 2021 07:35 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021
November 18, 2021 06:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases
November 04, 2021 06:30 ET | Centogene NV
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study
October 28, 2021 06:30 ET | Centogene NV
FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN)Study will enroll and genetically...
CENTOGENElogo.jpg
CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
October 06, 2021 08:00 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating...
CENTOGENElogo.jpg
CENTOGENE’s Ground-Breaking Family Genetic Research Published in the New England Journal of Medicine Reveals Path to Potential Cure for Structural Birth Defects
September 29, 2021 17:05 ET | CENTOGENE GmbH
Collaborative research utilized insights gained from CENTOGENE’s rare disease-centric Bio/Databank to help analyze data of more than 20,000 familiesEnabled testing of successful targeted therapeutic...
CENTOGENElogo.jpg
CENTOGENE Reports Second Quarter 2021 Financial Results
September 07, 2021 06:35 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021
September 01, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development
July 27, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting
June 25, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...